Home / Health / AI to Revolutionize Breast Cancer Pathology
AI to Revolutionize Breast Cancer Pathology
6 Oct
Summary
- Agendia to present AI-driven digital pathology for MammaPrint at ESMO 2026.
- AI approach analyzes routine whole slide images of breast cancer tissue.
- FLEX Study research to correlate genomic risk with biomarkers.
Agendia, Inc. is set to present groundbreaking research on an AI-driven digital pathology approach for its MammaPrint breast cancer test at the upcoming ESMO Congress 2026. This presentation, scheduled for October 24, 2026, in Madrid, highlights the development and validation of an AI method that analyzes standard whole slide images of breast cancer tissue.
This advancement in AI-driven digital pathology is crucial for increasing global access to vital genomic testing for breast cancer. The research aims to refine how genomic risk is assessed and understood, offering new insights for personalized treatment.
Further research from Agendia's ongoing FLEX Study will also be shared at ESMO 2026. Two poster presentations will detail the correlation between genomic risk and Ki67 levels, and the relationship between germline BRCA1 and BRCA2 mutations and gene expression profiling in a real-world patient population.
The FLEX Study, a large-scale prospective observational study, links comprehensive genomic data with clinical information from over 25,000 early-stage breast cancer patients worldwide. It plays a pivotal role in advancing the understanding of breast cancer biology and promoting equitable, personalized care.
